This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CARTITUDE-4 is a randomized, parallel-group phase 3 treatment trial in multiple myeloma. The registry describes a comparison of JNJ-68284528, a CAR-T therapy directed against B-cell maturation antigen (BCMA), with standard therapy consisting of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).
| Feature | CARTITUDE-4 |
|---|---|
| Trial name | CARTITUDE-4 |
| ClinicalTrials.gov identifier | NCT04181827 |
| Therapeutic area | Hematology |
| Condition | Multiple Myeloma |
| Phase | Phase 3 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 419 |
| Arms | 2 |
| Primary endpoint type | Time-to-event |
| Registered primary endpoints | 1 |
| Outcome measures posted | 20 |
| Trial status | Active, not recruiting |
| Lead sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry |
2. Clinical Question
The trial addresses a treatment comparison in participants with relapsed and lenalidomide-refractory multiple myeloma. The registry's brief title identifies JNJ-68284528 as a CAR-T therapy directed against B-cell maturation antigen (BCMA) and compares it with PVd or DPd standard therapy.
Population
Participants with relapsed and lenalidomide-refractory multiple myeloma.
Intervention
JNJ-68284528, identified in the registry data as ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy directed against BCMA.
Comparator
Standard therapy consisting of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).
Primary question
The registered primary efficacy question is expressed through progression-free survival from randomization to either documented progressive disease or death, whichever occurs first.
3. Trial Design
Standard Therapy: PVd or DPd
- Pomalidomide
- Bortezomib
- Dexamethasone
- Or daratumumab with pomalidomide and dexamethasone
JNJ-68284528
- Ciltacabtagene autoleucel (cilta-cel)
- CAR-T therapy directed against B-cell maturation antigen (BCMA)
4. Endpoints
The registry identifies progression-free survival (PFS) as the sole registered primary endpoint and classifies it as a time-to-event endpoint.
5. Statistical Methodology
The registry identifies PFS as a time-to-event endpoint. The appropriate statistical framework for a randomized PFS comparison ordinarily accounts for both the timing of events and right-censored observations.
Kaplan-Meier estimation
A Kaplan-Meier analysis is a standard way to estimate the PFS distribution when patients can be censored before experiencing progression or death. It estimates the probability of remaining event-free over time while retaining information from participants whose follow-up ends before an event.
Here, di represents events at event time ti, while ni represents the number at risk immediately before that time.
Hazard ratio
For a randomized two-arm time-to-event comparison, a Cox proportional-hazards model is commonly used to estimate a hazard ratio. A hazard ratio below 1 would indicate a lower estimated instantaneous event rate in the intervention group relative to the comparator under the model.
The hazard ratio is not a median survival ratio, an absolute risk difference, or the percentage of participants who benefit. Its interpretation depends on the time-to-event model and the data contributing to the analysis.
Log-rank comparison
A log-rank test is commonly used to compare time-to-event distributions between randomized treatment groups. It incorporates the ordering of event times and the number of participants at risk at each event time rather than treating follow-up as a simple binary outcome.
Analysis population
For a randomized efficacy endpoint such as PFS, the intention-to-treat principle is commonly used: participants are analyzed according to their randomized assignment. The ClinicalTrials.gov record does not specify the formal analysis population used for the posted PFS results, so no specific population definition is attributed to CARTITUDE-4 here.
6. Statistical Methods Explained
Why is PFS a time-to-event endpoint?
PFS records not simply whether progression or death occurred, but when the first qualifying event occurred. Participants who have not experienced progression or death during available follow-up may be censored. This makes ordinary proportions inadequate for fully describing the endpoint.
Why use Kaplan-Meier estimation?
Kaplan-Meier estimation allows participants with different lengths of follow-up to contribute information up to their event or censoring time. The resulting curve describes the estimated probability of remaining progression-free as follow-up proceeds.
What does a hazard ratio describe?
A hazard ratio compares the estimated instantaneous event rates between two groups within a specified time-to-event model. For example, an HR of 0.70 would be interpreted as an estimated instantaneous event rate approximately 30% lower in the intervention group, not as 30% fewer participants having an event.
Why is the confidence interval important?
A confidence interval communicates statistical uncertainty around an effect estimate. A narrow interval indicates greater precision than a wide interval, all else equal. It does not describe the range of individual patient outcomes.
Why does the p-value not measure effect size?
A p-value addresses evidence against a specified null hypothesis under the statistical model. It is affected by both the magnitude of the observed effect and the amount of information available. Consequently, a small p-value does not by itself indicate a large treatment effect.
What does censoring mean for PFS?
Censoring occurs when the event has not been observed by the end of the participant's usable follow-up, or when another prespecified censoring rule applies. Correct handling of censoring is important because the analysis assumes that censored participants can contribute appropriately up to their censoring time.
7. Planned Analysis
The registry's primary endpoint is PFS, measured from randomization (Day 1) to either progressive disease or death, whichever occurs first, for up to 3.9 years. For a randomized endpoint of this type, an appropriate formal analysis would ordinarily use a time-to-event framework such as Kaplan-Meier estimation together with a between-group comparison such as a log-rank test and an effect estimate such as a Cox-model hazard ratio.
Those methods explain how a PFS result would normally be evaluated; they do not establish what CARTITUDE-4 actually found.
8. Safety Results
The ClinicalTrials.gov record reports serious adverse events by arm. The available measure is the number of affected participants divided by the number at risk.
| Safety measure | Arm A | Arm B |
|---|---|---|
| Serious adverse events | 98/208 | 98/208 |
| Arm description | Standard Therapy: PVd or DPd | JNJ-68284528 (Ciltacabtagene Auto) |
What the reported fraction means
98/208 indicates that 98 affected participants were reported among 208 participants at risk in the registry-reported serious-adverse-event measure.
What it does not establish
The ClinicalTrials.gov record does not provide a formal hypothesis test, confidence interval, exposure-adjusted rate, adverse-event severity distribution, or causal attribution for these serious adverse events.
The reported numerators and denominators are identical across the two arms in the ClinicalTrials.gov record. That descriptive fact should not be expanded into a broader safety conclusion because the ClinicalTrials.gov record contains only this serious-adverse-event measure.
9. Understanding the PFS Analysis
The primary endpoint measures the time from randomization to the first qualifying progression or death. A survival-analysis approach therefore uses the timing of events rather than simply counting how many participants eventually experienced an event.
If the formal analysis reported an HR below 1 for JNJ-68284528 versus standard therapy, it would indicate a lower estimated instantaneous rate of progression or death under the fitted model. It would not mean that the same percentage of participants had their individual risk reduced by that amount.
The confidence interval would describe uncertainty around the estimated treatment effect under the analysis framework. It would not describe the range of PFS times for individual participants.
If a formal p-value were reported, it would quantify evidence against the specified null hypothesis under the prespecified statistical framework. It would not quantify the size or clinical importance of the treatment effect.
10. Censoring and the Proportional-Hazards Assumption
Two statistical issues are particularly important for interpreting any PFS analysis.
Censoring
Participants who do not experience progression or death during their available observation period contribute follow-up information until censoring. The validity of the analysis depends on appropriate prespecified censoring rules and assumptions about the censoring mechanism.
Proportional hazards
A conventional Cox hazard ratio has its simplest interpretation when the relative hazard is reasonably stable over time. If hazards vary substantially, a single HR can summarize a more complicated pattern imperfectly.
The registry-reported CARTITUDE-4 data do not provide the Kaplan-Meier curve, event-by-time information, censoring details, or proportional-hazards diagnostics. Those quantities therefore cannot be assessed from the ClinicalTrials.gov record.
11. Randomization and Causal Interpretation
Randomization is the central design feature identified in the ClinicalTrials.gov record. In a randomized comparison, treatment assignment is determined by the trial allocation mechanism rather than by a participant's subsequent outcome. This provides the basis for comparing outcomes between treatment groups without the same degree of treatment-selection confounding that can arise in observational comparisons.
The validity of this causal framework still depends on the actual trial conduct, prespecified analysis, endpoint definition, follow-up, and handling of post-randomization events.
Randomization does not guarantee identical observed characteristics in finite samples, nor does it eliminate uncertainty. Its principal statistical value is that, under the trial's design and assumptions, treatment assignment is not determined by the factors that subsequently generate the observed outcome.
12. Design Features That Are Not Specified in the Supplied Data
The ClinicalTrials.gov record supports several design conclusions, but they do not support every statistical detail that might appear in a full statistical analysis plan.
| Design topic | What can be stated from the ClinicalTrials.gov record |
|---|---|
| Randomization | Allocation is identified as randomized. |
| Parallel design | The design model is identified as parallel. |
| Masking | Masking is identified as none. |
| Primary purpose | Treatment. |
| Primary endpoint | Progression-free survival. |
| Endpoint type | Time-to-event. |
| Stratification factors | Not provided in the ClinicalTrials.gov record. |
| Randomization ratio | Not provided in the ClinicalTrials.gov record. |
| Non-inferiority margin | Not provided in the ClinicalTrials.gov record. |
| Crossover | Not provided in the ClinicalTrials.gov record. |
| Factorial design | Not identified; the registry-reported design model is parallel. |
| Multiplicity procedure | Not provided in the ClinicalTrials.gov record. |
| Interim-analysis procedure | Not provided in the ClinicalTrials.gov record. |
| Missing-data or imputation procedure | Not provided in the ClinicalTrials.gov record. |
| Bayesian methods | Not provided in the ClinicalTrials.gov record. |
This distinction is important. Absence of a detail from the ClinicalTrials.gov recordset is not evidence that the corresponding feature was absent from the actual protocol or statistical analysis plan.
13. Timeline
Trial start
The registry identifies June 12, 2020 as the study start date.
Primary completion
The registry identifies May 1, 2024 as the primary completion date.
Active, not recruiting
the ClinicalTrials.gov record lists the study status as ACTIVE_NOT_RECRUITING.
14. Why This Trial Matters Statistically
CARTITUDE-4 is a useful teaching example because its primary endpoint illustrates the core statistical structure of randomized time-to-event trials. The trial combines randomization, a clinically defined event endpoint, censoring, and longitudinal follow-up rather than reducing the primary analysis to a simple comparison of proportions.
| Concept | How it appears in CARTITUDE-4 |
|---|---|
| Randomization | The allocation is identified as randomized. |
| Parallel-group design | The registry identifies the design model as parallel. |
| Time-to-event analysis | PFS is the registered primary endpoint and is classified as time-to-event. |
| Kaplan-Meier estimation | A standard method for describing PFS over time. |
| Hazard ratio | A standard relative effect measure for randomized time-to-event comparisons. |
| Confidence interval | Would quantify uncertainty around a formal treatment-effect estimate. |
| Log-rank testing | A standard method for comparing time-to-event distributions between groups. |
| Cox regression | A standard model for estimating a hazard ratio for time-to-event outcomes. |
| Endpoint definition | PFS is based on first documented progression or death, whichever occurs first. |
| Safety comparison | Serious adverse events are reported as affected participants divided by participants at risk. |
15. Important Limitations
- No formal statistical-analysis records reported: although the trial data state that results are posted, no formal statistical analyses were posted. Consequently, no formal PFS effect estimate, confidence interval, or p-value is reported here.
- Limited safety detail: the ClinicalTrials.gov record contains only serious adverse events by arm, expressed as 98/208 in each arm.
- No subgroup results: the ClinicalTrials.gov record does not contain subgroup-specific efficacy estimates or interaction tests.
- No baseline table: demographic and clinical baseline characteristics are not included in the ClinicalTrials.gov record.
- No time-to-event estimates: median PFS, Kaplan-Meier probabilities, event counts, hazard ratios, and confidence intervals are not included in the ClinicalTrials.gov record.
- No detailed analysis-plan information: stratification, multiplicity, interim monitoring, missing-data rules, crossover, and Bayesian methods are not specified in the ClinicalTrials.gov record.
- Registry versus full statistical documentation: a registry record provides important trial information but does not necessarily reproduce every element of a protocol or statistical analysis plan.
16. What a Complete PFS Result Would Contain
For educational purposes, a complete statistical presentation of the registered primary endpoint would normally bring several pieces of evidence together.
Absolute information
Kaplan-Meier PFS estimates at clinically relevant time points and, where estimable, median PFS would describe the absolute time-to-event experience.
Relative information
A hazard ratio would summarize the relative event rate between randomized groups under a Cox-model framework.
Uncertainty
A confidence interval would show the statistical precision of the estimated treatment effect.
Hypothesis test
A prespecified p-value or other decision rule would quantify evidence against the relevant null hypothesis, subject to the trial's multiplicity and interim-analysis framework.
These components answer different questions. The hazard ratio is relative, the Kaplan-Meier curve is longitudinal, the median is a time-based summary, and the confidence interval describes uncertainty. None should be treated as a substitute for the others.
17. Statistical Concepts in This Trial
Learn more about the methods used in this trial:
18. Related Statistical Calculators
19. Sources
- ClinicalTrials.gov: CARTITUDE-4 (NCT04181827).
- PubMed: Publication indexed under PMID 41824255.
- PubMed: Publication indexed under PMID 41627370.
- PubMed: Publication indexed under PMID 41519141.
- PubMed: Publication indexed under PMID 40768190.
- PubMed: Publication indexed under PMID 40613875.
Continue through the Clinical Biostats statistical library
Explore tutorials and statistical calculators covering randomized trials, time-to-event endpoints, and related clinical-trial methods.
20. Record Summary
CARTITUDE-4 is a randomized, parallel-group phase 3 trial in relapsed and lenalidomide-refractory multiple myeloma, with 419 participants enrolled and two treatment arms. Its single registered primary endpoint is progression-free survival, defined from randomization (Day 1) to documented progressive disease or death, whichever occurs first, over a time frame of up to 3.9 years. The ClinicalTrials.gov record classifies the endpoint as time-to-event and indicate that results have been posted, but they contain no formal statistical-analysis records.
That distinction is central to a rigorous statistical review. The appropriate analytical framework for PFS involves time-to-event methods that can account for censoring, with Kaplan-Meier estimation, a between-group comparison such as the log-rank test, and a model-based effect measure such as a Cox hazard ratio commonly forming the statistical description. Those methods explain how the endpoint should be analyzed; they do not supply an outcome that is absent from the statistical-analysis data.